Passage BIO, Inc. (PASG) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Passage BIO, Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. The company's lead clinical product candidate, PBFT02, targets frontotemporal dementia (FTD-GRN). In July 2024, the company executed a strategic transition of its research collaboration from the University of Pennsylvania (Penn) to two new entities, GEMMA Biotherapeutics and Franklin Biolabs, resulting in the out-licensing of three pediatric programs (GM1, Krabbe, and MLD) to Gemma.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Loss | $(19,340) | $(27,110) | $(52,042) | $(85,304) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(0.49) | $(0.87) | $(1.56) |
| Research & Development Expenses | $8,656 | $15,098 | $30,621 | $49,258 |
| General & Administrative Expenses | $7,251 | $8,184 | $20,276 | $35,295 |
| Impairment of Long-Lived Assets | $4,795 | $5,390 | $5,233 | $5,390 |
| Cash, Cash Equivalents & Marketable Securities | $84,826 | $114,294 | $84,826 | $114,294 |
| Accumulated Deficit | $(646,510) | $(577,710) | $(646,510) | $(577,710) |
Note: Cash and marketable securities are combined for liquidity context. Q3 2024 Cash/Marketable Securities = $32,292 + $52,534 = $84,826.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by approximately 29% in Q3 2024 compared to Q3 2023. This was driven by a 43% reduction in R&D expenses and a 11% reduction in G&A expenses, primarily due to headcount reductions, the termination of discovery research obligations with Penn, and lower clinical activity for out-licensed programs.
- Impairment Charges: The company recorded $4.8 million in impairment charges in Q3 2024 related to the Hopewell Laboratory Space (Right of Use assets and property/equipment) following the execution of a sublease agreement.
- Liquidity Position: Total cash and marketable securities decreased from $114.3 million at December 31, 2023, to $84.8 million at September 30, 2024, reflecting operating cash burn partially offset by financing activities.
- Financing Activity: In March 2024, the company raised $8.7 million in net proceeds through its At-The-Market (ATM) facility. As of September 30, 2024, $50.0 million of capacity remains available under the ATM facility.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, marketable securities, and remaining payments from the Gemma Sublicenses ($5.0 million due in December 2024) to fund operations through the end of the second quarter of 2026.
- Pipeline Updates:
- PBFT02 (FTD-GRN): Cohort 1 dosing is complete; Cohort 2 enrollment is ongoing. 12-month follow-up data is expected in H1 2025.
- PBFT02 (FTD-C9orf72): Dosing expected to initiate in H1 2025 following positive regulatory feedback.
- PBFT02 (ALS): Regulatory feedback expected in H2 2024.
- Legal Contingency: A jury verdict in October 2024 awarded a former employee $1.0 million in a breach of contract claim. The company has accrued this amount in G&A expenses and is considering an appeal.
- Nasdaq Listing Risk: The company received notice in August 2024 that its stock price fell below the $1.00 minimum bid price requirement. It has an initial compliance period until January 28, 2025, to regain compliance or risk delisting.
- Going Concern: The company has incurred recurring losses and negative cash flows. While it currently expects to fund operations for the next 12+ months, it will require substantial additional capital to achieve profitability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $84.8 million cash balance against the projected burn rate to confirm the Q2 2026 liquidity timeline.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days prior to January 28, 2025, to avoid delisting.
- Gemma Transaction: Confirm receipt of the remaining $5.0 million initial payment from Gemma Biotherapeutics scheduled for December 2024.
- Legal Outcome: Track the status of the $1.0 million litigation verdict and any potential appeals or post-trial motions.
- ATM Facility Usage: Monitor future equity issuances under the remaining $50.0 million ATM capacity and potential dilution impacts.